Seyedeh Fatemeh Hashemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seyedeh Fatemeh Hashemi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Seyed Isaac Hashemy
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Abbas Alalikhan
Department of Chemistry, Faculty of Education, Al-Ayen Iraqi University, Dhi-Qar, Iraq; Department of Laboratory Medicine, Nasiriyah Heart Hospital, Dhi-Qar Health Directorate, Dhi Qar, Iraq; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication Amirali Reihani
Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication- Amirhossein Sahebkar
Mashhad University of Medical Sciences
1 shared publication - Hossein Hosseini
Department of Clinical Biochemistry, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran
1 shared publication - Mahdieh Aliyari
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication
Latest Publications
- 20 July 2024
- Published by Elsevier in Pathology - Research and Practice
- Vol. 261, 155479
Targeting the Akt signaling pathway: Exploiting curcumin's anticancer potential
- 20 July 2024
- Published by Elsevier in Pathology - Research and Practice
- Vol. 261, 155479
Targeting the Akt signaling pathway: Exploiting curcumin's anticancer potential
- Open Access
- 20 September 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 8082608
The Potential In Vitro Inhibitory Effects of Neurokinin‐1 Receptor (NK‐1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis
Background. Osteosarcoma, the most frequent osteogenic malignancy, has become a serious public health challenge due to its high morbidity rates and metastatic potential. Recently, the neurokinin‐1 receptor (NK‐1R) is proved to be a promising target in cancer therapy. This study is aimed at determining the effect of aprepitant, a safe and Food and Drug Administration (FDA) approved NK‐1R antagonist, on osteosarcoma cell migration and metastasis, and to explore its underlying mechanism of action. Methods. Colorimetric MTT assay was employed to assess cell viability and cytotoxicity. A wound‐healing assay was used to examine migration ability. The desired genes’ protein and mRNA expression levels were measured by western blot assay and quantitative real‐time PCR (qRT‐PCR), respectively. Gelatinase activity was also measured by zymography. Results. We found that aprepitant inhibited MG‐63 osteosarcoma cell viability in a dose‐dependent manner. We also observed that aprepitant inhibited the migrative phenotype of osteosarcoma cells and reduced the expression levels and activities of matrix metalloproteinases (MMP‐2 and MMP‐9). Aprepitant also reduced the expression of an angiogenic factor, VEGF protein, and NF‐κB as an important transcriptional regulator of metastasis‐related genes. Conclusion. Collectively, our observations indicate that aprepitant modulates the metastatic behavior of human osteosarcoma cells, which may be applied to an effective therapeutic approach for patients with metastatic osteosarcoma.
- 20 September 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 8082608
Open AccessThe Potential In Vitro Inhibitory Effects of Neurokinin‐1 Receptor (NK‐1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis
Background. Osteosarcoma, the most frequent osteogenic malignancy, has become a serious public health challenge due to its high morbidity rates and metastatic potential. Recently, the neurokinin‐1 receptor (NK‐1R) is proved to be a promising target in cancer therapy. This study is aimed at determining the effect of aprepitant, a safe and Food and Drug Administration (FDA) approved NK‐1R antagonist, on osteosarcoma cell migration and metastasis, and to explore its underlying mechanism of action. Methods. Colorimetric MTT assay was employed to assess cell viability and cytotoxicity. A wound‐healing assay was used to examine migration ability. The desired genes’ protein and mRNA expression levels were measured by western blot assay and quantitative real‐time PCR (qRT‐PCR), respectively. Gelatinase activity was also measured by zymography. Results. We found that aprepitant inhibited MG‐63 osteosarcoma cell viability in a dose‐dependent manner. We also observed that aprepitant inhibited the migrative phenotype of osteosarcoma cells and reduced the expression levels and activities of matrix metalloproteinases (MMP‐2 and MMP‐9). Aprepitant also reduced the expression of an angiogenic factor, VEGF protein, and NF‐κB as an important transcriptional regulator of metastasis‐related genes. Conclusion. Collectively, our observations indicate that aprepitant modulates the metastatic behavior of human osteosarcoma cells, which may be applied to an effective therapeutic approach for patients with metastatic osteosarcoma.